Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014162007> ?p ?o ?g. }
- W2014162007 endingPage "2675" @default.
- W2014162007 startingPage "2657" @default.
- W2014162007 abstract "The insulin-like growth factor-2 mRNA-binding proteins 1, 2, and 3 (IGF2BP1, IGF2BP2, IGF2BP3) belong to a conserved family of RNA-binding, oncofetal proteins. Several studies have shown that these proteins act in various important aspects of cell function, such as cell polarization, migration, morphology, metabolism, proliferation and differentiation. In this review, we discuss the IGF2BP family’s role in cancer biology and how this correlates with their proposed functions during embryogenesis. IGF2BPs are mainly expressed in the embryo, in contrast with comparatively lower or negotiable levels in adult tissues. IGF2BP1 and IGF2BP3 have been found to be re-expressed in several aggressive cancer types. Control of IGF2BPs’ expression is not well understood; however, let-7 microRNAs, β-catenin (CTNNB1) and MYC have been proposed to be involved in their regulation. In contrast to many other RNA-binding proteins, IGF2BPs are almost exclusively observed in the cytoplasm where they associate with target mRNAs in cytoplasmic ribonucleoprotein complexes (mRNPs). During development, IGF2BPs are required for proper nerve cell migration and morphological development, presumably involving the control of cytoskeletal remodeling and dynamics, respectively. Likewise, IGF2BPs modulate cell polarization, adhesion and migration in tumor-derived cells. Moreover, they are highly associated with cancer metastasis and the expression of oncogenic factors (KRAS, MYC and MDR1). However, a pro-metastatic role of IGF2BPs remains controversial due to the lack of ‘classical’ in vivo studies. Nonetheless, IGF2BPs could provide valuable targets in cancer treatment with many of their in vivo roles to be fully elucidated." @default.
- W2014162007 created "2016-06-24" @default.
- W2014162007 creator A5007987372 @default.
- W2014162007 creator A5044359653 @default.
- W2014162007 creator A5065864748 @default.
- W2014162007 creator A5067689926 @default.
- W2014162007 creator A5076894374 @default.
- W2014162007 creator A5080831504 @default.
- W2014162007 creator A5085748857 @default.
- W2014162007 date "2012-10-16" @default.
- W2014162007 modified "2023-10-17" @default.
- W2014162007 title "Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?" @default.
- W2014162007 cites W1491870867 @default.
- W2014162007 cites W1524308920 @default.
- W2014162007 cites W170749850 @default.
- W2014162007 cites W1841068357 @default.
- W2014162007 cites W1869550773 @default.
- W2014162007 cites W1959450586 @default.
- W2014162007 cites W1963717607 @default.
- W2014162007 cites W1963789550 @default.
- W2014162007 cites W1964465683 @default.
- W2014162007 cites W1971946120 @default.
- W2014162007 cites W1972850724 @default.
- W2014162007 cites W1975849543 @default.
- W2014162007 cites W1975966075 @default.
- W2014162007 cites W1976033611 @default.
- W2014162007 cites W1976637923 @default.
- W2014162007 cites W1978609960 @default.
- W2014162007 cites W1982237691 @default.
- W2014162007 cites W1982401101 @default.
- W2014162007 cites W1983609064 @default.
- W2014162007 cites W1984090022 @default.
- W2014162007 cites W1984219521 @default.
- W2014162007 cites W1984240217 @default.
- W2014162007 cites W1986172894 @default.
- W2014162007 cites W1986679962 @default.
- W2014162007 cites W1987194984 @default.
- W2014162007 cites W1987841488 @default.
- W2014162007 cites W1988610157 @default.
- W2014162007 cites W1989624726 @default.
- W2014162007 cites W1990138726 @default.
- W2014162007 cites W1991173762 @default.
- W2014162007 cites W1991469669 @default.
- W2014162007 cites W1992357827 @default.
- W2014162007 cites W1996237444 @default.
- W2014162007 cites W1996260131 @default.
- W2014162007 cites W1997574653 @default.
- W2014162007 cites W1997988932 @default.
- W2014162007 cites W1999177329 @default.
- W2014162007 cites W2000104627 @default.
- W2014162007 cites W2000639076 @default.
- W2014162007 cites W2002158796 @default.
- W2014162007 cites W2002530816 @default.
- W2014162007 cites W2004079122 @default.
- W2014162007 cites W2005608256 @default.
- W2014162007 cites W2008121442 @default.
- W2014162007 cites W2008131643 @default.
- W2014162007 cites W2009668185 @default.
- W2014162007 cites W2011326170 @default.
- W2014162007 cites W2011915177 @default.
- W2014162007 cites W2012141216 @default.
- W2014162007 cites W2029213510 @default.
- W2014162007 cites W2029277937 @default.
- W2014162007 cites W2030021527 @default.
- W2014162007 cites W2031125959 @default.
- W2014162007 cites W2031498113 @default.
- W2014162007 cites W2032554396 @default.
- W2014162007 cites W2037688075 @default.
- W2014162007 cites W2038309580 @default.
- W2014162007 cites W2038320333 @default.
- W2014162007 cites W2040666864 @default.
- W2014162007 cites W2040774413 @default.
- W2014162007 cites W2040985383 @default.
- W2014162007 cites W2043379458 @default.
- W2014162007 cites W2043534094 @default.
- W2014162007 cites W2045857960 @default.
- W2014162007 cites W2047148095 @default.
- W2014162007 cites W2051823680 @default.
- W2014162007 cites W2052209686 @default.
- W2014162007 cites W2053001481 @default.
- W2014162007 cites W2053003053 @default.
- W2014162007 cites W2053135283 @default.
- W2014162007 cites W2053613923 @default.
- W2014162007 cites W2054020024 @default.
- W2014162007 cites W2055117238 @default.
- W2014162007 cites W2058427048 @default.
- W2014162007 cites W2060383954 @default.
- W2014162007 cites W2061224512 @default.
- W2014162007 cites W2061273744 @default.
- W2014162007 cites W2061370408 @default.
- W2014162007 cites W2062114042 @default.
- W2014162007 cites W2064140502 @default.
- W2014162007 cites W2069706974 @default.
- W2014162007 cites W2071277481 @default.
- W2014162007 cites W2073482890 @default.
- W2014162007 cites W2073963904 @default.
- W2014162007 cites W2082182386 @default.
- W2014162007 cites W2083693481 @default.